# Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer

> **NCT07059676** · — · NOT_YET_RECRUITING · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Ovarian Cancer

## Interventions

- **DRUG:** Zejula (Niraparib)

## Key facts

- **NCT ID:** NCT07059676
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059676, "Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07059676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*